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Abstract 
Stem cells are the central element of regenerative medicine (RM). However, in many 
clinical applications the use of scaffolds fabricated with biomaterials is required. In 
this sense, mesoporous bioactive glasses (MBGs) are going to play an important role 
in bone regeneration because their striking textural properties, quick bioactive 
response and biocompatibility. As the other bioactive glasses, MBGs are mainly 
formed by silicon, calcium and phosphorus oxides whose ions play an important role 
in cell proliferation as well as in homeostasis and bone remodeling process. A 
common improvement of bioactive glasses for RM is by adding small amounts of 
oxides of elements that confer them additional biological capacities, including 
osteogenic, angiogenic, antibacterial, anti-inflammatory, haemostatic or anticancer 
properties. Moreover, MBGs are versatile in terms of the different ways in which they 
can be processed such as scaffolds, fibers, coatings or nanoparticles. MBGs are 
unique because their textural properties are so high that they still exhibit outstanding 
bioactive responses even after adding extra inorganic ions or being processed as 
scaffolds or nanoparticles. Moreover, they can be further improved by loading with 
biomolecules, drugs and stem cells. This article reviews the state of the art and future 
perspectives of MBGs in the field of RM of hard tissues. 
 
Keywords: mesoporous bioactive glasses; regenerative medicine; bone 











Regenerative medicine (RM) emerged from clinical practices such as the design 
of surgical implants, the use of biomaterials-based scaffolds or the transplant of 
organs or bone marrow and is closely related to tissue engineering [1-3]. Said 
practices has limitations, like the loss of prostheses with time, the inflammatory 
process induced by the scaffolds, the contamination of the bone marrow aspirate or 
the need to take immunosuppressive drugs after organ transplantation. The bases of 
RM are human stem cells [4-6] that can be of adult or embryo-derived origin, and 
also they can be the so-called induced pluripotent stem (iPS) cells obtained by 
reprogramming adult cells. Human embryos are not the ideal source. Therefore, 
obtaining iPS cells is an attractive approach as it involves the transfer of genes to 
human cells which brings RM close to gene and cell therapies (Figure 1).  
 
Figure 1. Foundations of Regenerative Medicine and its relationships with other advanced therapies.  
Researchers specializing in cells generally try to use the minimum possible 
amount of synthetic biomaterials. However, biomedical industry of tissue 
regeneration is combining cellular therapies with others based on genes, biomaterials 








pharmaceuticals and biomedical prostheses. For example, RM seeking cartilage 
regeneration restoration can give way to a rational development of prosthetics.  
Moreover, there is a growing link between gene therapy and RM. Cell therapy seeks 
to place genes in cells to implant them. The current interest in reprogramming adult 
cells into iPS cells is driving the linkage between genes and cells in the use of a 
genetic approach to several therapies.  
Typically, regeneration describes the process by which lost specialized tissue is 
replaced by the proliferation of specialized cells. In humans, the process is limited to 
a few tissues, such as bone [7,8]. In this sense, the goal of RM is to regenerate 
mainly by supplying cells, particularly stem cells that can stimulate a broader 
regeneration. Similarly, repair is the replacement of lost tissue with granulation tissue 
that matures to form scar tissue. Organ regeneration is different from organ repair 
after an injury [9]. Repair leads to the restoration by synthesis of scar tissue without 
restoration of normal tissue. Since the ultimate goal of RM is to return the patient to a 
healthy state, repair can be considered to fall within technologies such as surgery. In 
most cases, the goal of regeneration is to restore a deteriorated function.  
RM includes tissue engineering, genetic engineering and molecular activators 
and is an interdisciplinary research field focused on the repair, replacement or 
regeneration of cells, tissues or organs to restore the deterioration of function 
resulting from birth defects, diseases, trauma or aging [10]. RM uses several 
approaches that move it beyond traditional transplant and replacement therapies that 
may include the use of biomolecules, gene therapy, stem cells transplantation, tissue 
engineering, and reprogramming of cell and tissue types [3,11].  
At the present, there are commercial products based on RM to treat skin ulcers 
or knee cartilage injuries (Figure 2). These therapies often include a scaffold 
fabricated with biomaterials. More therapies involving embryonic stem cells and 
temporary scaffolding are expected to appear but, in the situations where structural 
tissue is needed, it is difficult for cells alone to succeed. Therefore, although stem 
cells are the central element of RM, many clinical applications need the use of 
scaffolds, often fabricated with bioceramics [12]. In bone regeneration, autografts, the 
current gold standard, have many limitations including morbidity or a limited amount 
of material available [13-15]. In this area, synthetic grafts obtained with RM-
approaches using mesoporous bioactive glasses (MBGs) [16-20] are going to play a 









Figure 2. Many applications of RM require the use of biomaterials behaving as scaffolds of the stem 
cells as are the MBGs for hard tissues regeneration. 
 
2. Mesoporous glasses in the context of bioactive glasses 
Bioactive glasses (BGs) are known for 50 years when the first melt-prepared 
bioactive glass (MPG) belonging to the SiO2–Na2O–CaO–P2O5 system was reported 
by Hench et al [21]. These materials, prepared by the traditional method of 
quenching of a melt, are dense materials, which exhibit a particular surface reactivity 
when contact with aqueous biological fluids leading the formation of a mechanically 
strong bond between the biomaterial and living bone. This unusual property, denoted 
as bioactivity in the field of biomaterials, is greatly sought in the development of new 
biomaterials for regenerate bone. Other bioactive materials, most of them 
bioceramics, were reported including calcium phosphates, such as hydroxyapatite 
[22], or glass-ceramics, such as Apatite/Wollastonite glass ceramic [23]. However, 
none of the biomaterials described so far has exhibited a bioactive response as quick 
as BGs, which, as a result of their partial solubility in contact with physiological fluids, 








medium. In particular, the Si (IV) ions, the major component of BGs, that benefits the 
presence of extracellular events, including angiogenesis and the Ca2+ ions that 
contribute to cell proliferation and exhibit osteogenic activity, as well as play a very 
important role in gene transfection [24,25]. 
MPGs showed room for improvement, considering the expected increase of 
glasses reactivity if obtained as porous materials with high specific surface areas and 
a greater number of silanol groups (Si-OH) on their surface. Thus, in the 1990s, Li et 
al proposed the synthesis of porous BGs by sol-gel, a wet chemistry method [26]. 
Glasses so obtained are denoted as “gel glasses” or sol-gel glasses (SGGs). These 
glasses exhibit high surface areas and nanometric pores in a great diversity of sizes. 
The wide distribution of pores sizes of SGGs does not allow an optimal control of the 
release of biomolecules and drugs if these glasses are used as matrixes for drug 
delivery systems (DDS). The sol-gel method does not allow controlling the SGGs 
nanostructure, but the microstructure and, consequently, their in vitro and in vivo 
behaviors can be controlled with different synthesis parameters like type and 
concentration of catalyst used for the tetraethyl orthosilicate (the SiO2 source) 
hydrolysis, the proportion of water or the glass composition [27-29]. Moreover, sol-gel 
method allows processing BGs in complex forms such as fibers or coatings.  
To improve the SGGs capabilities, in 2004 Yan et al [30] described the 
synthesis of so called mesoporous bioactive glasses (MBGs). The synthesis method 
is based in the sol-gel chemistry and supramolecular chemistry principles. A 
surfactant that acts as a template to control the glasses nanostructure is added. The 
surfactants used to synthesize MBG are amphiphilic molecules capable of self-
assembling in aqueous solutions when a certain concentration – called critical 
micellar concentration (cmc) – is reached. At that point, mesophases formed guide 
the obtaining of ordered arrangements of mesoporous channels with virtually 
identical pore diameter.  
Figure 3 shows the method of synthesis of MBGs called Evaporation-Induced 
Self Assembly (EISA), proposed by Brinker et al [31]. As observed, after the 
surfactant removal, in this case Pluronic® 123, glasses exhibiting highly ordered 
arrangements of mesopores with diameters around 5 nm in a very narrow pores size 
distribution are obtained [17,32,33]. MBGs can be considered as intermediate 
materials between SGGs and pure silica mesoporous materials, such as MCM-41, 








2001 were proposed by Vallet-Regi et al as matrices for drug release systems [35]. 
Their very narrow mesopore size distribution and highly ordered mesopore structure 
convert MBGs in materials that allow a high control of the processes of load and 
release of biomolecules and drugs. Therefore, they are candidates to be used in 
DDS. Moreover, due to their excellent textural properties, MBGs exhibit, as it will be 
described below, faster bioactive responses than MPGs and SGGs. 
 
Figure 3. Schematic representation of the EISA method of synthesis used to obtain MBGs. 
 
Currently, MBGs are often obtained as nanoparticles (MBGNs) that, having a 
smaller, controlled particle size, allow increasing the efficiency of proper transfection 
and the ability to release biomolecules and genes [36-38]. These nanoparticles 
contain ordered mesopores with sizes between 5 and 10 nm and the particle size can 
be tailored by modifying the solvent and the surfactant concentration. Indeed, the 
effect of the concentration of surfactant on the characteristics of MBGs has been 
widely investigated [39,40]   
Figure 4 schematically depicts in a comparative way the time and temperature 
conditions used for the syntheses of the three families of BGs. As seen, MPGs 
synthesis requires shorter times, less than one day, but much higher temperatures, 
close to 1400 oC, which supposes extra energy costs. However, the production of 
SGGs and MBGs requires around 7 d, but take place at lower temperatures, for most 








calcination and stabilization. In both cases this stage requires thermal treatments 
close to 700oC for a few hours. Regarding the first stages of synthesis of SGGs and 
MBGs, Figure 4 also shows that in the SGGs synthesis the stages of aging and 
drying of the gels (from day 3 to 6)  are carried out at temperatures somewhat above 
than RT. In general, gel ageing takes places at temperatures around 70 oC and the 
drying stage rarely exceeds 150 oC. However, in the MBGs synthesis the stages of 
gelation, aging and drying are performed at constant temperature close to 30 ºC. 
These lower temperatures used for the synthesis of SGGs and MBGs represent 
lower energy expenditures, although the alkoxides used as sources of SiO2, 
tetraethyl orthosilicate (TEOS) and P2O5, triethyl phosphate (TEP), are more 
expensive than the inorganic precursors used for the synthesis of MPGs. Moreover, 
the most common CaO source in these cases is Ca(NO3)24H2O.  
 
Figure 4. Schematic representation of the time vs temperature conditions used to obtain the three 
families of bioactive glasses. 
 
Therefore, it can be summarized that the most significant distinctive features of 
the three families of BGs are the higher temperatures required to obtain MPGs and 
the longer times and more expensive reactants required to synthesize SGGs and 
MBGs. However, control over the mesostructure in MBGs is significant because it 








3. Textural properties of mesoporous glasses 
Although the three families of BGs may have a similar or identical chemical 
composition, MPGs are easily distinguished from the other two types because they 
are dense materials. Thus, their porosity is null and their specific surface can be 
considered negligible when used as monoliths and very small when used as 
particles. However, SGGs and MBGs are highly porous materials. In addition, MBGs 
exhibit outstanding structural and textural properties. The synthesis and 
characterization of several SGGs and MBGs of interest as bioceramics can be found 
respectively in [41] and [42]. The most significant textural and mesostructural 
features of the three families of BGs are shown in Figure 5 in comparative way.  
 
Figure 5.  Comparison of the textural properties (surface area, pore volume) typically exhibited by the 
three families of BGs. HR-TEM images of the two porous glasses, SGGs and MBGs, are included. 
As it is represented in Figure 5, the pore volume and the surface area in 
MBGs are approximately double than in SGGs of analogous composition. 
Furthermore, as can be seen in the High-Resolution Transmission Electron 
Microscopy (HR-TEM) images, the main difference between the two types of porous 
glasses is that SGGs exhibit a great diversity of pore sizes and they are disordered. 
Whereas, in MBGs all mesopores display almost identical size and they are ordered, 








parameters, MBGs with 3D-cubic mesopores arrangements can be obtained [40]. In 
short, the three families of BGs exhibit the amorphous structure of glasses at the 
atomic scale, but MBGs also exhibit an ordered mesopore structure which confers 
upon them the outstanding properties that make them optimal materials to use in RM 
of bone. A recent application of MBGs under investigation, outside of bones and teeth 
repair, is for soft tissues engineering applications [44]. 
 Therefore, SGGs and MBGs are different at the mesoscale. The remarkably 
high textural properties of MBGs are close to those of ordered mesoporous materials 
made of pure silica, such as MCM-41 and SBA-15. However, mesoporous silica 
materials have a very moderate or null in vitro bioactive response when soaked in 
simulated body fluid (SBF). This fact demonstrates that the huge textural properties 
of mesoporous silica materials –surface areas around 1000 m2/g with pore volumes 
over 1 cm3/g – and the large amount of silanol groups they have on the surface do 
not guarantee a bioactive response in SBF [45]. Compared to these materials, MBGs 
have lower textural properties, but still unusually high, and the presence of CaO and 
P2O5 together with SiO2 give them the optimal reactivity to be coated with 
hydroxycarbonate apatite (HCA) after being soaked for very short periods in SBF. 
So-called in vitro bioactivity tests in SBF monitor the time it takes for the HCA layer to 
form. The shorter the time, the more bioactive a biomaterial is considered to be.  
Nitrogen adsorption/adsorption isotherms of MBGs are analogous to SGGs. 
Both kinds of glasses show type IV isotherms, characteristic of mesoporous 
materials, as well as type H1 hysteresis loops, characteristic of cylindrical pores open 
at both ends. However, in SGGs the pore diameter distribution obtained was broader 
and the textural parameters of MBGs are approximately twice than SGGs [32]. 
(Figure 5).  
Another difference between SGGs and MBGs is that the textural properties of 
SGGs are related to its composition, particularly to the CaO content. When CaO 
increases, the surface area decreases and the pore volume increases. However, for 
MBGs the variation in the CaO proportion mainly affects the symmetry of the 
mesopore arrangement, which can evolve from a 2D-hexagonal structure (p6mm) to 
a 3D-bicontinuous cubic structure (Ia-3d). This variation in symmetry can also be 










4. Bioactive response of mesoporous glasses 
Regarding the in vitro bioactive response, MPGs exhibited bioactivity for SiO2 
contents between 45 and 60 mol%. In this point it must be highlighted the low SiO2 
contents of a MPG to exhibit a bioactive response if compared with glasses designed 
for other technological applications, which are close to 70 %. Thus, the composition 
of Hench Bioglass®, the first bioactive material, has an unusually low SiO2 content. 
This yields a glass reactive enough in aqueous media to experience a series of 
chemical processes that result in the formation of a nanocrystalline HCA layer on the 
glass surface, which is considered indicative of a bioactive response.  
The left part of Figure 6 shows the first five stages of the Hench mechanism that 
explains the formation of a strong union between a BG and bone [46]. The full 
mechanism consists of 11 stages; the last six include the participation of biological 
entities. However, the first five stages only depend on the intrinsic reactivity of the 
BG, and they take place both in vivo and in vitro. Therefore, they are the stages that 
are usually assessed in simulated biological solutions such as Kokubo´s SBF [47]. It 
must be considered that although this mechanism was proposed for MPGs, it can be 
applied to SGGs, because the differences in the bioactive kinetics of both types of 
glasses are minimum. However, there are significant differences with MBGs that 
justify the extremely rapid bioactive response of these glasses. 
 
Figure 6. The first five stages of the Hench mechanism for the in vitro HCA formation on MPGs and 








Most of the SGGs and MBGs investigated as biomaterials belong to the SiO2–
CaO–P2O5 system. Our research group reported the influence of P2O5 in the 
bioactive response of BGs, a component that slightly speeds up the kinetics of 
formation of the HCA layer, but is not an indispensable requisite for bioactivity [43]. 
For this reason, some compositions of SGGs widely investigated even some ones 
commercial, are P2O5- free and belong to the SiO2–CaO system.  
Even though the high surface area and porosity of SGGs expands the bioactivity 
window up to SiO2 contents of 90 mol-% in SGGs, the bioactivity mechanism is 
similar for MPGs and SGGs. In both families of BGs, an average period of time 
ranging from 3 to 7 days to form the nano-HCA layer is considered appropriate to 
consider these glasses as potential candidates for bone regeneration. However, 
MBGs exhibit noticeably quicker in vitro bioactivity results. For instance, some MBG 
compositions were coated by the HCA layer after only 4 h in SBF. These MBGs are 
the synthetic materials that display the fastest bioactive response described. The 
right-hand side of Figure 6 shows the differences that can explain the extremely quick 
bioactive response of MBGs. First difference is the lower pH value as a consequence 
of the stages 1 to 3 accelerated and extended. The second difference is the 
formation of octacalcium phosphate, detected in the maturation process of bone but 
never before observed in the in vitro tests as an intermediate phase that evolves to 
nano-HCA.   
 
5. Clinical applications of the three families of bioactive glasses 
Figure 7 displays the main clinical applications of the three families of BGs in a 
comparative way. As is observed, each family exhibits the features of the previous 
one, increased with additional ones. Thus, MPGs are excellent biomaterials to be 
used as bone grafts due to their quick bioactive response and possibilities for 
improvement such as the inclusion of therapeutic inorganic ions in their composition 
and the possibility of processing them to obtain scaffolds and composites.  
In addition to those capabilities, SGGs offer others arising from their wet 
chemistry processing at low temperatures. First, the considerable expansion of the 
bioactivity window to include SiO2 contents of up to 90 mol-% consequence of the 
excellent textural properties. However, this fact is of scarce relevance for their clinical 








because their higher concentration of surface silanol groups and that some 
biocompatible polymer can be added during their syntheses at low temperatures to 
obtain organic-inorganic hybrid materials [49], also called nanocomposites, with the 
desired mechanical or degradation properties. Also, by selecting the appropriate 
moment during the sol to gel transition, it is possible use this method of synthesis to 
obtain coatings or fiber meshes of SGGs.    
 
Figure 7. Expansion of the biological capabilities of bioactive glasses when going from MPGs to 
SGGs and MBGs. 
Finally, MBGs, which can be considered an improvement of SGGs, show all the 
characteristics of MPGs and SGGs, but presents another new ones as a result of its 
synthesis in the presence of surfactants, which produces a great control over the 
MBGs mesostructure. As it was told, textural properties of MBGs are more 
advantageous than those of SGGs, and its in vitro bioactive responses much faster 
than of any other BGs family. Moreover, the large volume of monodisperse pores 
makes MBGs ideal candidates to host drugs and biomolecules, which is essential for 
their use in bone RM applications and DDS. On the other hand, one of the current 
most active areas of study in the MBGs field is obtaining as nanoparticles that can be 
used as nanocarriers of biologically active ions and biomolecules. [36]. This field that 








6. Mesoporous bioactive glasses in regenerative medicine of bone  
The remarkable quick bioactive response of MBGs is not the only aspect that 
should be considered when selecting a bioactive glass for RM of bone. The new 
physical/chemical features and the processing possibilities provided by wet chemistry 
synthesis methods to obtain coatings and fibers must be also taken into account. 
Moreover, the great pore volume and control over the morphology and size of pores 
in MBGs provides the capability to load them with osteogenic biomolecules that, 
together with their remarkably fast bioactive response, makes these materials optimal 
candidates for use as scaffolds in RM [50,51].   
Figure 8 shows the main capabilities and properties of MBGs, including the 
potential to obtain as nanoparticles (MBGNs) and also to add additional ions to those 
that usually make them up like silicon and calcium [52-54]. Thus, Si (IV) ions favor 
certain cellular events and the angiogenesis and Ca2+ ions contribute to cell 
proliferation and the osteogenic activity exerting a crucial role in gene transfection.  
As can be seen, the addition of certain ions considered therapeutic [55,56], it is easy 
to do because the composition of glasses can be easily altered in an almost infinite 
compositional range bringing additional advantages including osteogenic, 
angiogenic, anticancer or bactericidal properties [57-61]. 
 








As it was said, another important capability of MBGs in RM is their ability to load 
and release drugs. However, in this area the concept of drug, generally used as a 
substance with antibiotic, anticancer or anti-inflammatory properties, expands to 
other types of biomolecules such as growth factors, bioactive proteins, enzymes or 
non-viral genes, such as DNA or RNA. (See Figure 9). 
 
Figure 9. The number of substances typically considered as drugs and their requirements is expanded 
when used for living tissues regeneration. 
7. Mesoporous glasses as scaffolds, microparticles or nanoparticles  
 In clinical application MBGs can be used mainly as scaffolds and also as 
particles, which are considered nanoparticles when they are less than 100 nm in size 
[62]. However, for practical purposes nanoparticles are also considered when their 
dimensions slightly exceed that value. On the other hand, it is also common in the 
literature to list as nanoparticles of MBGs to particles with sizes of 500 or even 800 
nm [36]. Particles of these dimensions may also be useful in bone RM applications 
but they should rather be considered as sub-micrometric particles or as 
microparticles when exceeding 1000 nm size.  
One of the first attempts to obtain scaffolds tailored to clinical necessities 
involved the preparation of an injectable paste made of MBGs that was able to set as 
a calcium phosphate bone cement [63], However, this material failed in the 
macroporous architecture required for a scaffold useful in RM because it only 
exhibited random macroporosity and had poor pore interconnectivity. The 








that could be optimum candidates for bone regeneration was achieved in 2008 [43]. 
This study used rapid prototyping equipment that allowed obtaining scaffolds with a 
pre-designed macroporosity.  
Keeping in mind the need for 3D hierarchical scaffolds for bone regeneration, 
several strategies were proposed to design the macroporosity required for functions 
such as bone cell ingrowths, nutrient supply and vascularization, as well as for the 
adhesion and development of bone cells. These strategies include foaming, freeze 
drying, fiber bonding or rapid prototyping (RP) technologies [64]. In all cases it is very 
important to confirm that the processing of MBG powders to obtain scaffolds does not 
eliminate ordered mesoporosity or bioactivity decorating with cells theMBG surfaces.  
 Our research group has widely investigated MBG scaffolds obtained by rapid 
prototyping to apply in bone RM [65-67]. With the manufacturing technique used, 3D 
scaffolds with hierarchical porosity were obtained. Indeed, this method of 
manufacture allows obtaining biomaterials exhibiting mesopores around 5 nm, which 
are especially appropriated to host drugs, pores close to 5 m in size, formed during 
the evaporation of the solvent used for preparing the printing ink, that are essential 
for cell adhesion and growth and also pores close to 1 mm that are obtained in the 
printing process and that allow the scaffolds to be colonized with cells and blood 
vessels. The micrographs of Figure 10 show images corresponding to thee three 
categories of pores present in the MBG scaffolds obtained by rapid prototyping and 
the main roles that each type of pore plays in bone RM.  
 
Figure 10. Three types of pores in MBG scaffolds: Giant channels, around 1 mm, macropores, close 








Other methods of synthesis were successfully used to obtain 3D porous scaffolds 
with meso-macroporosity based on MBGs including the polyurethane sponge method 
[68] or pouring a suspension of MBG powders in polyvinyl alcohol (PVA) into a 
negative template of polylactic acid (PLA) that was subsequently removed by 
extraction. [69].  
 
8. .Expanding mesoporous glass properties by adding inorganic ions   
A characteristic of glasses, regardless of the method of synthesis used, is that 
they can be obtained in a practically infinite range of compositions. Indeed, during the 
synthesis of glasses by quenching a melt to be used in industrial applications, 
besides the main components, it is common to add small amounts of other oxides, a 
process often called doping, to confer upon them certain mechanical, optical, 
electrical, etc. properties. Similarly, in the design of glasses for bone regeneration, 
many researchers have explored the doping of BGs with oxides of elements with 
well-known biological activity, e.g., osteogenic, angiogenic or bactericidal properties 
[55]. When these studies are carried out on the three families of BGs, the limitation 
on doping is the ability of these extra elements to be integrated into the glass network 
without eliminate their bioactive response and maintaining biocompatibility, and, in 
the case of SGGs and MBGs, without an excessive deterioration of their textural 
properties. 
The doping of MBGs with ions of elements with biological activity, often denoted 
as therapeutic ions, is a subject investigated with great interest in recent years 
[70,71]. In these studies, the first objective is to determine the maximum amount of 
the extra oxide that can be incorporated into the MBG network to exert the desired 
biological action, but maintaining the necessaries bioactivity, biocompatibility and 
ordered mesoporosity. A comprehensive list of the elements included so far in the 
MBGs composition and the biological activity sought in each case are shown in 










Figure 11. Elements included so far in the MBGs and their biological activity. Solid lines indicate well-
established properties, while the dashed lines correspond to biological effects proposed.  
The first point that catches your attention in the Figure 11 is the large number of 
elements that have been investigated, practically most of those considered non toxic. 
In this sense, the absence of elements such as Cr, toxic in certain oxidation states, 
Ni, which produces an allergic reaction in a growing portion of the population, or Al, 
which has been related to neurological disorders, can be highlighted. Likewise, the 
inclusion of elements already present in very large quantities in the human body, 
such as C or N, and others extremely abundant in extracellular or intracellular fluids, 
such as Na, K, or Cl, were not investigated either. Moreover, it can be mentioned the 
small, but increasing presence, of elements with high atomic numbers whose 
presence in the human body as essential elements is minimal.  
Regarding the chemical elements of investigated, we can start with the 
biological action of the three basic elements of the MBGs, i. e, Si, Ca and P, to which 
an angiogenic character is attributed and, in the case of the first two, also osteogenic 
[36]. With respect to the therapeutic elements of interest in the present article, we can 
observe that, in addition to the biological actions investigated several years ago like 
angiogenic, antibacterial and osteogenic, new actions were recently added, like anti-
inflammatory, antitumor, hemostatic, antiangiogenic, cancer preventive or to 








To understand the criteria used in the Figure 11, we must indicate that the solid 
lines signify well-established properties on which there is a broad consensus on the 
part of the scientific community, while the dashed lines correspond to biological 
effects more recently proposed or with a minor consensus degree. For instance, Li is 
considered anti-inflammatory and proposed as osteogenic [72], B is considered 
angiogenic and proposed as osteogenic [73], Se, is recently proposed as 
antiangiogenic and cancer preventive [74], Ta, which is gaining much recent notoriety 
as a hemostatic agent [75], and so on. Likewise, the presence of several lanthanide 
therapeutic elements investigated to be added to MBGs, such as Ce [76], Sm [77], 
Eu [78] or Tb [79], must be highlighted. As is observed, many other elements are 
under investigation, in several cases more than one decade ago, including Ti, V, Mn, 
Fe, Co, Cu, Zn, Ga, and Sr, [61,80-87]. Moreover, studies about new elements added 
to MBGs are frequently published, for example, the recently investigated antibacterial 
and antioxidant properties of Te [88]. 
Up to now, our research group sometimes in collaboration with other groups, 
has been deeply interested in investigate the effect of include Co, Cu, Zn, Ga, Sr and 
Ce in MBGs with SiO2 contents close to 80 % [16,89-95]. Particularly, we have 
developed MBG scaffolds containing 4% of ZnO, already investigated in three animal 
models. Finally to mention that, as is observed in Figure 11, many chemical elements 
exhibit osteogenic and angiogenic capabilities and that several of them like Zn, Cu, 
Mn, Ga and Ce are very versatile exerting several beneficial biological actions.  
On the other hand, when investigating the addition of an extra oxide to a MBG, 
generally with composition SiO2CaO or SiO2CaOP2O5, the first step is perform 
the synthesis with increasing amounts of the new oxide to determine the maximum 
amount able to be incorporated without eliminating the bioactive response or the 
mesoporous order. Then, biocompatibility in vitro assays and others must be 
performed to check that the extra oxide does indeed provide the desired property. 
Finally, the in vivo evaluation of biocompatibility and the biological activity of this 
extra element must be assessed.  
Therefore, a simple way to improve the biological behavior of any BG is through 
the addition of therapeutic ions; however, this process will modify the 
physicochemical properties of the initial glass. In the case of MBGs, a slight decrease 
in the kinetics of the bioactive response is observed and a decrease of about 40% in 








starting values for undoped MBGs are so high that substituted MBGs remain useful 
for their intended use for bone RM and also as matrixes for controlled drug delivery 
systems, DDS, as will be seen in the following section. 
9. Loading mesoporous glasses with biomolecules and drugs 
Bone regeneration relies in three basic pillars: stem cells, signal molecules and 
scaffolds. In this last pillar, MBGs processed into 3D macroporous scaffolds are 
considered to be the finest option for bone regeneration for the reasons exposed in 
previous sections. MBG-based scaffolds designed for RM must exhibit 
interconnected and hierarchical porosity. Thus, as observed in Figure 10, they must 
contain giant pores (channels) and macropores to allow angiogenesis and interaction 
with cells [60] and  pores in the range between 2 and 10 nm like those in MBGs, 
optimum to host and release substances with biological activity. Such mesopores 
allow biomolecules with different biological activities to be included in the scaffolds 
[96].  Particularly, signal molecules can be included for RM of bone regeneration that 
induce bone formation, such as Bone Morphogenetic Protein (BMP) [97], growth 
factors like Vascular Endothelial Growth Factor (VEGF) [98], or different fractions of 
Parathyroid Hormone related Peptide (PTHrP) [99]. Table 1 collects a number of 









Table 1. Drugs and biomolecules that can be loaded in MBGs and its biological activity. 
Drugs and biomolecules Main biological action  
Angiogenic   
DEX, dexamethasone & QK peptide QK peptide that mimics the α-helical structure of VEGF 100 
VEGF, Vascular Endothelial Growth Factor  Stimulates blood vessels formation 101 
Sreptokinase Dissolves blood clots formed in blood vessels 102 
DMOG, Dimethyloxaloylglycine Used in hypoxia-induciblefactor (HIF) activity assays 103 
Antibacterial   
Amoxicillin Antibiotic semi-synthetic (beta-lactam) 104 
Ciprofloxacin Antibiotic (second-generation fluoroquinolone)  105 
Gentamicin Antibiotic aminoglycoside 90 
Levofloxacin Antibiotic synthetic (fluoroquinolone) DNA replication inhibitor 90 
Moxifloxacin Antibiotic (fluoroquinolone) 106 
Rifampicin Antibiotic semi-synthetic 90 
Teicoplanin Antibiotic for prophylaxis and treatment Gram-positive bacteria 107 
Tetracycline        Antibiotic of broad spectrum  108 
Triclosan Antibacterial and antifungal agent  109 
Vancomycin  Antibiotic glycopeptides, Gram-positive bacteria effective 90 
Vancomycin / Tetracycline Antibiotics  110 
Anticancer   
Isothiocyanate Cancer-preventive activity  111 
Aflatoxins anti-bodies Carcinogens and mutagens produced by molds  112 
Mitomycin C Chemotherapy agent with antitumor activity 113 
Cisplatin Chemotherapy agent to treat cancer 114 
DOX, doxorubicin  Chemotherapy medication to treat cancer 115 
DOX/ Vancomycin Chemotherapy medication to treat cancer / antibiotic 110 
Osteogenic   
BMP, bone morphogenetic protein Bone and cartilage formation   116 
Icariin Osseous fractures repair  117 
Osteostatin Osteogenic activity, anti-resorptive  93 
DEX,  dexamethasone Osteogenic differentiation 118 
Phenamil Osteogenic, triggers osteoblastic differentiation & mineralization 119 
rh-BMP-2, recombinant human BMP Osteoinductive mesenchymal cells to chrondroblasts & osteoblasts 120 
Ipriflavone Osteoporosis: prevention and treatment  121 
Other functions   
ACE, angiotensin converting enzyme/IBU   High blood pressure  and heart failure / anti-inflammatory  122 
Aspirin  Anti-inflammatory non steroidal  123 
BSA, Bovine serum albumin Cell nutrient and enzymes stabilizer  124 
Chlorhexidine  Disinfectant and antiseptic   125 
Curcumin Multiple roles: cancer, anti-inflammatory, antioxidant, anti-arthritic 126 
EGF, Epidermal growth factor Cell growth and differentiation stimulation 127 
Fluorescein Diagnosis  128 
IBU, Ibuprofen Anti-inflammatory non steroidal  129 
Metoclopramide Treatment of heartburn and of ulcers and sores in oesophagus 70 








As can be seen in the Table, a considerable number of drugs and biomolecules 
have been loaded in MBGs, and very likely the inclusion of more substances will be 
investigated soon. An inspiration to identify other biologically active substances of 
interest to be loaded in MBGs can be found in our comprehensive review article 
regarding drugs and biomolecules loaded in pure silica mesoporous materials. Such 
materials have similarities with MBGs because both families exhibit nanopores and a 
great number of surface silanol groups [96].  
The great number of drugs and biomolecules included in Table 1, were grouped 
attending their biological action as angiogenic, antibacterial, anticancer, osteogenic 
and other functions, such as anti-inflammatory or disinfectant or various types of 
treatment or diagnosis. Because the table is already self-explanatory, only a few 
comments not able to be found in the table will be done here. For instance, the most 
investigated antibacterial substance so far is gentamicin, which was investigated in 
more than 8 papers, although vancomycin and ciprofloxacin also appear in several 
articles on the subject. Likewise, doxorubicin was investigated in more than 10 
publications as anticancer drug. Moreover, dexamethasone and BMPs for its 
osteogenic action and ibuprofen for its anti-inflammatory action also aroused a great 
interest to be loaded in MBGs.  
On the other hand, our research group has a wide experience in using the 
fraction 107-111 of this peptide, i.e., PTHrP107-111, which is usually denoted as 
osteostatin, and sometimes TRSAW which is represented in Figure 12. The Figure 
shows the five amino acids forming this pentapeptide and the beneficial biological 
effects that make it a promising osteoinductor substance, which some authors 










Figure 12. Osteostatin, a pentapeptide, fragment of parathormone related peptide (PTHrP), with 
excellent features to be used as an osteoinductor signal in RM of bone. 
 
10.  Interaction of stem cells with mesoporous glasses in bone regeneration 
Numerous studies have evaluated biocompatibility of MBGs in the presence of 
different cell lines. A recent review article by Saletes et al [131] identified around 100 
articles of the period between 2015 and 2021 investigating the interactions of MBGs 
and living cells. The main results of 63 these papers were displayed in a highly 
comprehensive Table. Regarding the MBGs scaffolds, more used compositions were 
those with SiO2 contents of 58%, 64%, 80% or 85%. In many case adjuvants as 
polycaprolactone, PCL, chitosan or polymethyl methacrylate, PMMA were used and 
often the MBGs were doped with inorganic elements such as Ga, Cu, Sr, Ce or nano-
Ti to increase the biological capabilities of the MBGs. Several cell lines were used for 
the studies, including MC3T3-E1 mouse osteoblast cell line, MG-63: human 
osteoblast-like, human Saos-2, osteoclast-like cells, murine RAW264.7 murine 
macrophages, human umbilical vein endothelial cells, HUVECs, and others.  
Furthermore, and of a great interest of interest in the framework of the present 
article, in 20 of the articles described in [131], the biocompatibility of MBGs was 
investigated in the presence of bone mesenchymal stem cells (BMSCs), in most 
cases of rat (rMSCs) or human origins (hMSCs), but also obtained from a donor 
rabbit. Despite the differences in the MBG compositions, in all cases the excellent 
cytocompatibility of MBGs was shown, evidenced by the enhanced proliferation of 








the ionic dissolution products amplified adhesion, proliferation, and the osteogenic 
differentiation of MSCs and the proliferative and the in vitro angiogenic ability of 
HUVECs. 
The use of MSCs for bone RM still arouses certain controversy [132-134]. 
Effectively, due to the difficulties inherent in in vivo studies, there are relatively few 
published results and also a great variability of methods, protocols and animal 
models that impedes to compare the results obtained by the different research 
groups. However, most authors trust that the union of MSCs with scaffolds and signal 
molecules will be the solution [135], although at this time it is perceived still far away. 
On the other hand, our research group has recently reported the 
biocompatibility of MBGs in the presence of hMSCs under in vitro [66] and also in 
vivo conditions, after be implanted in an animal model in New Zealand rabbit [99]. 
The MBG scaffolds investigated contained 4% of ZnO, because the osteogenic and 
bactericidal features of Zn2+ ions, and were loaded with osteostatin (OST) an 
osteoinductive and antiresorptive pentapeptide. The in vitro study [66] showed an 
excellent internalization of hMSCs cells in the MBG scaffolds and outstanding 
responses of in terms of cell adhesion, growth and osteogenic differentiation. This 
system allowed us to disclose, for the first time, a synergistic effect of zinc and 
osteostatin to enhance hMSCs cell growth and differentiation, suggesting its potential 
for bone regeneration. 
The excellent in vitro results prompted us to carry out in vivo studies [99]. The 
investigated systems exhibited bone regeneration capability. However, the trabecular 
bone to volume density values obtained by μCT showed that the good bone healing 
capability of pristine Zn-MBG was significantly improved by the scaffolds enriched 
with OST and hMSCs. These in vivo findings suggest the interest of these MBG 
complete systems to improve bone repair in the clinical practice. New in vivo studies 
with different animal models and in in one case using rabbit MSCs instead of hMSCs 
are in progress.  
 
11. Present of mesoporous glasses in bone regenerative medicine 
In the Figure 13 are schematically depicted possible improvements of the 








materials exhibiting an extremely quick bioactive response. The scaffolds fabricated 
from MBGs powders can be improved by adding inorganic ions, biochemical signals, 
antibiotics or other molecules with biological activity and stem cells [126, 136-139]. 
Some examples of each element are indicated in the Figure 12. For instance, Cu2+ 
ions as a therapeutic inorganic ion and osteostatin as biochemical signal. Regarding 
the drugs able to be hosted and released from the mesopores, four antibiotics were 
selected and mesenchymal stem cells as cells decorating the scaffolds surface. It 
must be highlighted that the biological properties brought by each of the additional 
elements are indicated at the bottom of the Figure. 
 
Figure 13. Strategies used to improve MBG scaffolds adding bactericidal, angiogenic and osteogenic 
capabilities. 
The two main current trends regarding the use of MBGs in RM applications are 
based on processing them as 3D scaffolds exhibiting hierarchical porosity or as 
nanoparticles. The biological capabilities of the starting MBGs of the CaO–P2O5–SiO2 
system are extended by adding relatively small amounts of diverse inorganic oxides. 








additional biological capabilities as osteogenic, angiogenic, bactericidal, anti-
inflammatory, anticancer or hemostatic.  
The processing of MBG powders into scaffolds or nanoparticles and the 
inclusions of therapeutic inorganic ions produce a decrease in both the textural 
properties and the bioactive response of the resultant biomaterials. However, one of 
the main strengths of MBGs is that the original values of these parameters are so 
high that even after some decrease they still are enough to be excellent candidates 
as bone grafts in RM. Furthermore, the processing and the additions of inorganic ions 
sometimes partially destroy the order of mesopores, but for most clinical applications 
this partial order designated as worm-like order is sufficient. Bioactive glasses 
exhibiting worm-like order show lower textural properties and bioactivity that well 
ordered MBGs but still higher than traditional SGGs. 
If MBGs are compared with the other families of bioactive glasses, we can 
observe that MPGs are excellent biomaterials for bone graft substitution because 
their quick bioactive response and possibilities to be improved with therapeutic 
inorganic ions and to be processed in scaffolds and composites. In addition to all the 
above, SGGs offer new capabilities as the considerable expansion of the bioactivity 
window up to 90 mol-% of SiO2, the possible surface functionalization and obtaining 
organic-inorganic hybrids with tailored mechanical or degradation properties [49] and 
the obtaining of coatings or fiber meshes. Finally, MBGs, that can be considered an 
improvement of SGGs, exhibit controlled nanostructure and huge textural properties 
because their synthesis in the presence of surfactants and in vitro bioactive 
responses much faster than the other families of BGs. Moreover, the large volume of 
monodisperse pores makes MBGs ideal candidates to host biomolecules and drugs, 
an essential feature for their use in applications in bone RM. 
 
12. Future perspective of mesoporous glasses in bone regenerative medicine 
Several issues have to be addressed regarding the use of MBGs in RM, including:  
 The extra elements added to MBGs sometimes bind so strongly with the glass 
network that the desired biological action is not observed because the inorganic 
ions are not released to the surrounding medium. For instance, our group 
investigated a MBG including Ga2O3 because the bactericidal properties of Ga
3+ 








assays because the Ga3+ ions remained in the glass network without being 
released to the medium [89]. To solve that this drawback we designed new Ga-
MBGs able to release concentrations of Ga3+ within the therapeutic range [91] 
which now need further investigations.   
 Often, the necessary concentrations of an inorganic element to achieve a 
biological effect, for instance bactericidal properties, are so high that the MBG 
obtained is not biocompatible. In this sense, we investigated MBGs enriched with 
4 and 7 mol-% ZnO looking for the osteogenic and bactericidal capabilities of Zn2+ 
ions. The MBG with 7% of ZnO exhibited the highest antibacterial capability. 
However, this material was not cytocompatible [89]. Therefore, the MBG with 4% 
of ZnO was selected for our later in vitro and in vivo studies [66,93,99]. The lower 
bactericidal capability of this MBG was proposed to be improved by adding small 
amounts of antibiotics [90]. The MBG with 4 % of ZnO continue under study as a 
very promising candidate to be used in bone RM.         
 Sometimes, when the MBG scaffolds or nanoparticles are loaded with biologically 
active substances like biomolecules and drugs, the interaction of such substances 
with the therapeutic ions can substantially modify their release kinetics. Such 
release kinetics can also be modified by the partial solubility of the MBG in 
physiological medium. That way, our group investigated MBGs scaffolds loaded 
with curcumin, which exhibits numerous positive biological effects including its 
possible uses as bactericidal [140] an alternative anticancer drug [141]. We 
observed that the presence of some inorganic ions in the glass network increased 
the amount of curcumin able to be uploaded into the MBG scaffold. However, in 
some cases the interactions of the drug with the inorganic ions was so strong that 
the curcumin release was hindered [126]. Thus, we learnt that when several 
components are included in a MBG, all the possible interactions between them 
must be investigated because they can influence their biological behaviour.  
 Another factor that must be considered arises from the high bioactivity of MBGs-
based biomaterials. In some cases, the quick formation of an apatite-like layer 
coating the MBG surface when it contacts to biological fluids can hinder or slow 
down the release of the biomolecules, drugs or therapeutic ions in the MBGs.  
 Other unexpected effect was observed when the MBGs scaffolds were coated 
with thin gelatin layer (6 wt-%) to increase their mechanical integrity and made 








[99]. Gelatin layer was slightly swelled with the surrounding fluids improving the fit 
of the scaffold into the bone defect. Moreover, the gelatin layer scarcely 
decreased the textural properties of MBGs, but the in vitro studies showed that it 
substantially improved the interchange of ions, biomolecules and drugs between 
the biomaterial and medium [66]. Consequently, MBGs trying to be brought to the 
clinic must be thoroughly characterized after any small variation in the processing 
parameters and after the sterilization and packaging processes.        
 When the system becomes more complicated with the addition of therapeutic 
ions, drugs, signals and living cells, researchers must consider not only the 
interactions of each element with the matrix, but also the interactions among 
elements. For instance, when we loaded the MBGs scaffolds with the osteogenic 
peptide osteostatin, an unexpected synergic effect was observed among the Zn2+ 
ions and the peptide in terms of increasing the bone regeneration [66]. Similarly, 
when the MBG scaffolds were implanted, a synergic effect between osteostatin 
and mesenchymal stem cells was observed [99].  
 One of the current most active areas of study in the MBGs is obtaining them as 
nanoparticles (MBNs) to be used as nanocarriers of biologically active ions and 
biomolecules [36]. One of the aspects to clarify is the size of the particles to 
consider them as true nanoparticles. In general, nanoparticles must be smaller 
than 100 nn, but for pure silica nanoparticles, particles around 120 nm are 
admitted in this category. However, in MBGs, particles up to 800 nm were 
reported as nanoparticles when they rather must be considered as 
submicrometric particles. This field, which is subjected to a great expansion, 
ought to produce soon materials with new capabilities for bone RM. However, 
much research is needed before reaching the clinical use. 
 Other approaches based on conventional routes and also more imaginative ones 
must be explored. For instance, the enrichment of MBGs with an on with double 
oxidation state, such as Ce3+/Ce4+, exhibits an interesting behavior because 
inhibits oxidative stress by mimicking catalase enzyme activity [76]. Other 
approaches could be tracing the degradation products from MBGs with isotopic 
labeling such as 45Ca [54] or the use of molecular modeling [142] to understand 









Considerable research work is required before MBGs can be used clinically in 
humans. However, at the moment it is clear that 3D scaffolds and nanoparticles 
based on CaO–P2O5–SiO2 MBGs, enhanced with oxides of metals with biological 
activity, loaded with biological signals and decorated with stem cells is one of the 
most promising approaches for RM of bone tissues.  
ACKNOWLEDGMENTS 
The authors would like to acknowledge funding provided by European Research 
Council, Advanced Grant Verdi-Proposal No. 694160 (ERC-2015-AdG) and the 
Instituto de Salud Carlos III, grant number PI20/01384, co-funded with European 
Union FEDER funds. 
13. References 
[1]  A.S. Mao, D. J. Mooney, Regenerative medicine: Current therapies and future directions, 
Proc. Natl. Acad. Sci. U S A, 112 (2015) 14452–14459. doi: 10.1073/pnas.1508520112. 
[2] G.C. Chang Chien, A. Stogicza, Regenerative Medicine in: S. Pangarkar, Q.G. Pham, 
B.C. Eapen (Eds.) Pain Care Essentials and Innovations 2021, pp 245–253.  
doi:10.1016/B978-0-323-72216-2.00017-X. 
[3] C. Mason, P. Dunnill, A brief definition of regenerative medicine, Regen. Med, 3 (2008) 1-
5. doi: 10.2217/17460751.3.1.1. 
[4] N. Rajabzadeh, E. Fathi, R. Farahzadi, Stem cell-based regenerative medicine, Stem Cell 
Investig. 6 (2019) 19. doi: 10.21037/sci.2019.06.04 eCollection 2019. 
[5] J.-F. Stoltz, N. de Isla, Y. P. Li, D. Bensoussan, L. Zhang, C. Huselstein, Y. Chen, V. 
Decot, J. Magdalou, N. Li, L. Reppel, Y. He, Stem Cells Int. 2(015) 734731. doi: 
10.1155/2015/734731.  
[6] C. Nombela-Arrieta, J. Ritz L.E. Silberstein, The elusive nature and function of 
mesenchymal stem cells, Nat. Rev. Mol. Cell Biol 12 (2011) 126–131. doi: 
10.1038/nrm3049. 
[7] P.V. Giannoudis, H. Dinopoulos, E. Tsiridis, Bone substitutes: An update, Injury 36 (2005) 
S20–S27. doi: 10.1016/j.injury.2005.07.029.  
[8] R. Dimitriou, E. Jones, D. Mcgonagle, P.V. Giannoudis, Bone regeneration: current 
concepts and future directions. BMC Medicine 9 (2011) 66. doi:10.1186/1741-7015-9-66.  
[9] I.V. Yannas, Tissue and Organ Regeneration in Adults, Springer, New York, 2001. doi 
10.1007/978-1-4939-1865-2 
[10] H.L Greenwood , P.A Singer, G.P Downey, D.K Martin, H. Thorsteinsdóttir, A.S Daar,  









[11] G. Sampogna, S.Y. Guraya, A. Forgione, Regenerative medicine: Historical roots and 
potential strategies in modern medicine, J. Microsc. Ultrastruct, 3 (2015) 101–107. doi: 
10.1016/j.jmau.2015.05.002. 
[12] C. Wu, J. Chang, Bioceramics to regulate stem cells and their microenvironment for 
tissue regeneration. Mater. Today 24 (2019) 41–56. doi:10.1016/j.mattod.2018.07.016.  
[13] H.C. Pape, A. Evans, P. Kobbe, Autologous Bone Graft: Properties and Techniques, J. 
Orthop. Trauma. 24 (2010) S36–S40. doi: 10.1097/BOT.0b013e3181cec4a1. 
[14] C. Laurencin, Y. Khan, S.F El-Amin, Bone graft substitutes, Expert. Rev. Med. Devices 
3: (2006) 49–57. doi: 10.1586/17434440.3.1.49. 
[15] T.T. Roberts, A.J. Rosenbaum, Bone grafts, bone substitutes and orthobiologics the 
bridge between basic science and clinical advancements in fracture healing. 
Organogenesis. 8 (2012) 114–124. doi: 10.4161/org.23306 
 [16] A.J. Salinas, M. Vallet-Regi, Glasses in bone regeneration: a multiscale issue. J. Non-
Cryst. Solids 432 (2016) 9–14. doi: 10.1016/j.jnoncrysol.2015.03.025.  
[17] A,J. Salinas, Mesoporous Bioactive Glasses: State of the Art and Future Prospects, In: 
Bioactive Glasses: Properties, Composition and Recent Applications, D. Arcos Maria 
Vallet-Regi Eds. Nova Series: Materials Science and Technologies, NY, 2020, pp 243–
274. 
[18] C. Migneco, E.Fiume, E. Verné, F. Baino, A Guided Walk through the World of 
Mesoporous Bioactive Glasses (MBGs): Fundamentals, Processing, and Applications. 
Nanomaterials, 10 (2020) 2571. doi: 10.3390/nano10122571.  
[19] M. Vallet-Regí, A.J. Salinas, Mesoporous bioactive glasses in tissue engineering and 
drug delivery. In: A.R. Boccaccini, D.S. Brauer, L. Hupa, editors. Bioactive glasses: 
fundamentals, technology and applications. London (UK): The Royal Society of 
Chemistry. pp. 393–419. 2017.  
[20] S. Kargozar, M. Montazerian, S. Hamzehlou, H. W. Kim, F. Baino. Mesoporous bioactive 
glasses: Promising platforms for antibacterial strategies. Acta Biomater. 1 (2018) 1–19. 
doi: 10.1016/j.actbio.2018.09.052. 
 [21] L.L. Hench, R.J. Splinter, W.C. Allen, T.K. Greenlee, Bonding mechanisms at the 
interface of ceramic prosthetic materials. J. Biomed. Mater. Res. 2 (1971) 117–141. doi: 
10.1002/jbm.820050611. 
[22] H. W. Denissen, K. de Groot, P. Ch. Makkes, A. van den Hooff, P. J. Klopper, Tissue 
response to dense apatite implants in rats, J. Biomed. Mater. Res. 14 (1980) 713–721. 
doi: 10.1002/jbm.820140603. 
[23] T. Kokubo, M. Shigematsu, Y. Nagashima, M. Tashiro, T. Nakamura, T. Yamamuro, S. 
Higashi, Apatite- and wollastonite-containing glass-ceramics for prosthetic application, 








[24] A. J Salinas, M. Vallet-Regi, J. Heikkilä, Use of bioactive glasses as bone substitutes in 
orthopedics and traumatology. In: Bioactive glasses. 2nd ed. Ed. H. Ylanen Woodhead 
Publishing. 337–364. 2018. 
[25] M. Montazerian, E. D. Zanotto, A guided walk through Larry Hench’s monumental 
discoverie. J. Mater. Sci. 52 (2017) 8695–8732. doi: 10.1007/s10853-017-0804-4 
[26] R. Li, A.E. Clark, L.L. Hench, An investigation of bioactive glass powders by sol-gel 
processing, J. Appl. Biomater. 2 (1991) 231–239. doi: 10.1002/jab.770020403.  
[27] M. Vallet-Regí, C.V. Ragel, A.J. Salinas, Glasses with medical applications. Eur. J. 
Inorg. Chem. (6) (2003)1029–1042. doi: 10.1002/ejic.200390134. 
[28] D. Arcos, M. Vallet-Regí, Sol–gel silica-based biomaterials and bone tissue 
regeneration, Acta Biomater. 6 (2010) 2874–2888. doi: 10.1016/j.actbio.2010.02.012. 
[29] J.R. Jones, Review of Bioactive Glass: From Hench to Hybrids. Acta Biomaterialia 9 
(2013) 4457–4486.  doi: 10.1016/j.actbio.2012.08.023. 
 [30] X. Yan, C. Yu, X. Zhou, J. Tang, D. Zhao. Highly ordered mesoporous bioactive glasses 
with superior in vitro bone-forming bioactivities, Angew. Chem. Int. Ed. Engl. 43 (2004) 
5980–5984. doi: 10.1002/anie.200460598. 
[31] C.J. Brinker, Y. Lu, A. Sellinger, H. Fan, Evaporation‐Induced self‐assembly: 
nanostructures made easy, Adv. Mater. 11 (1999) 579–585. doi:10.1002/(SICI)1521-
4095(199905)11:7. 
 [32] I. Izquierdo-Barba, A.J. Salinas, M. Vallet-Regí, Bioactive glasses: from macro to nano, 
Int. J. Appl. Glass Sci. 4 (2013)149–161. doi: 10.1111/ijag.12028. 
[33] A. López-Noriega, D. Arcos, I. Izquierdo-Barba, Y. Sakamoto, O. Terasaki, M. Vallet- 
Regí, Ordered mesoporous bioactive glasses for bone tissue regeneration. Chem. Mater. 
18 (2006) 3137–3144. doi:10.1021/cm060488o. 
[34] C.T Kresge, M.E. Leonowitz, W.J. Roth, J.C. Vartuli, J. S Beck. Ordered mesoporous 
molecular sieves synthesized by a liquid-crystal template mechanism. Nature 359 (1992) 
710–712. doi: 10.1038/359710a0.  
[35] M. Vallet-Regí, A. Ramila, R.P. del Real, J. Perez-Pariente, A New Property of MCM-41:  
Drug Delivery System, Chem. Mater. 13 (2001) 308–311. doi: 10.1021/cm0011559. 
 [36] H. Zhu, K. Zheng, A.R. Boccaccini, Multi-Functional Silica-Based Mesoporous Materials 
as Co-Delivery Systems for Biologically Active Ions and Therapeutic Biomolecules. At 
SSRN: https://ssrn.com/abstract=3770987 or http://dx.doi.org/10.2139/ssrn.3770987. 
[37] A.M. El-Kady, M.M. Farag, A.M.I. El-Rashedi, Bioactive glass nanoparticles designed for 
multiple deliveries of lithium ions and drugs: Curative and restorative bone treatment, 









 [38] Q. Liang, Q. Hu, G. Miao, B. Yuan, X. Chen, A facile synthesis of novel mesoporous 
bioactive glass nanoparticles with various morphologies and tunable mesostructure by 
sacrificial liquid template method, Mater. Lett. 148 (2015) 45–49. doi: 
10.1016/j.matlet.2015.01.122. 
[39] A. Kumar, A. Aditya, S. Murugavel, Effect of surfactant concentration on textural 
characteristics and biomineralization behavior of mesoporous bioactive glasses, Mater. 
Sci. Eng. C, 96 (2019) 20–29, doi: 10.1016/j.msec.2018.11.003. 
[40] C. Shih, C.-S. Chien, J.-C. Kung, J.-C. Chen, S.-S. Chang, P.-S. Lu, C.J. Shih, Effect of 
surfactant concentration on characteristics of mesoporous bioactive glass prepared by 
evaporation induced self-assembly process, Appl. Surf. Sci., 264 (2013) 105–110,  doi: 
10.1016/j.apsusc.2012.09.134. 
[41] A.J. Salinas, A.I Martin, M. Vallet-Regí, Bioactivity of three CaO-P2O5-SiO2 sol-gel 
glasses. J. Biomed. Mater. Res. 61 (2002) 524–532. doi: 10.1002/jbm.10229.  
[42] N. Gómez-Cerezo, L. Casarrubios, I. Morales, M.J .Feito, M. Vallet-Regí, D. Arcos, M.T. 
Portolés, Effects of a mesoporous bioactive glass on osteoblasts, osteoclasts and 
macrophages. J. Colloid Interface Sci. (2018) 528, 309–320. doi: 
10.1016/j.jcis.2018.05.099. 
[43] H. Yun, S. Kim, Y. Hyeon, Preparation of 3D cubic ordered mesoporous bioactive 
glasses. Solid State Sci. 10 (2008) 1083–1092. doi: 
10.1016/j.solidstatesciences.2007.11.037. 
[44] F. Baino, G. Novajra, V. Miguez-Pacheco, A.R. Boccaccini, C. Vitale-Brovarone, 
Bioactive glasses: Special applications outside the skeletal system, J. Non-Cryst. Solids, 
432, A (2016) 15–30,  doi: 10.1016/j.jnoncrysol.2015.02.015. 
[45] M. Vallet-Regí, L Ruiz-González, I. Izquierdo-Barba, J.M. González-Calbet, Revisiting 
silica based ordered mesoporous materials: medical applications, J. Mater. Chem. 16 
(2006) 26–31.  doi: 10.1039/B509744D. 
[46] L.L. Hench, Bioceramics: From Concept to Clinic, J. Am. Ceram. Soc. 74, (1991) 1487–
1510. doi: 10.1111/j.1151-2916.1991.tb07132.x. 
[47] Kokubo T, Takadama H. How useful is SBF in predicting in vivo bone bioactivity? 
Biomaterials. 27 (2006) 2907–15. doi: 10.1016/j.biomaterials.2006.01.017.  
[48] M. Vallet-Regi, A.J. Salinas. Role of the short distance order in glass reactivity Materials 
11 (2018), 415. DOI:10.3390/ma11030415. 
[49] A.I. Martín, A.J Salinas, M. Vallet-Regí, Bioactive and degradable organic-inorganic 
hybrids, J. Europ. Ceram. Soc. 25 (2005) 3533–3538. doi: 
10.1016/j.jeurceramsoc.2004.09.030. 
[50] A.J. Salinas, P. Esbrit, M. Vallet-Regí, A tissue engineering approach based on the use 









[51] A. J. Salinas, M. Vallet Regi, Bioactive ceramics: from bone grafts to tissue engineering. 
RSC Advances 3 (2013) 11116–11131. doi: 10.1039/c3ra00166k.  
[52] Y. Li, B.P. Bastakoti, Y. Yamauchi, Smart Soft‐Templating Synthesis of Hollow 
Mesoporous Bioactive Glass Spheres, Chemistry, 21 (2015) 8038–8042. doi: 
10.1002/chem.201406570. 
[53] K. Zheng, B. Sui, K. Ilyas, A.R. Boccaccini, Porous bioactive glass micro- and 
nanospheres with controlled morphology: developments, properties and emerging 
biomedical applications. Mater. Horiz., 8 (2021) 300–335. doi: 10.1039/D0MH01498B.   
[54] B. Sui, G. Zhong, J. Sun, Drug-loadable Mesoporous Bioactive Glass Nanospheres: 
Biodistribution, Clearance, BRL Cellular Location and Systemic Risk Assessment via 
45Ca Labelling and Histological Analysis, Scientific Reports, 6 (2016) 33443. doi: 
10.1038/srep33443. 
[55] A. Hoppe, N.S. Guldel, A.R. Boccaccini, A review of the biological response to ionic 
dissolution products from bioactive glasses and glass-ceramics. Biomaterials 32 (2011) 
2757–2774. doi: 10.1016/j.biomaterials.2011.01.004 
[56] A.J. Salinas, S. Shruti, G. Malavasi, L. Menabue, M. Vallet-Regí, Substitutions of cerium, 
gallium and zinc in ordered mesoporous bioactive glasses, Acta Biomater. 7 (2011) 
3452–3458. doi: 10.1016/j.actbio.2011.05.033. 
[57] C. Wu, J. Chang, Y. Xiao, Mesoporous Bioactive Glasses for Drug Delivery and Bone 
Tissue Regeneration. In: Advanced Bioactive Inorganic Materials for Bone Regeneration 
and Drug Delivery. Eds: C. Wu, J. Chang, Y. Xiao, CRC Press pp 1–24 (2013). 
[58] C. Wu, J. Chang, Multifunctional mesoporous bioactive glasses for effective delivery of 
therapeutic ions and drug/growth factors. J. Control. Release, 193 (2014) 282–295. doi: 
10.1016/j.jconrel.2014.04.026. 
[59] L.B. Romero-Sanchez, M. Marí-Beffa, P. Carrillo, M.A. Medina, A. Díaz-Cuenca, 
Copper-containing mesoporous bioactive glass promotes angiogenesis in an in vivo 
zebrafish model. Acta Biomater. 68 (2018) 272–285. doi: 10.1016/j.actbio.2017.12.032. 
[60] S. Kargozar, F. Baino, S. Hamzehlou, R.G Hill, M. Mozafari, Bioactive glasses: sprouting 
angiogenesis in tissue engineeering. Trends Biotechnol. 36 (2018) 430–444. doi: 
10.1016/j.tibtech.2017.12.003. 
[61] S. Kargozar, F. Baino, S. Hamzehlou, M. R. Hamblin, M. Mozafari. Nanotechnology for 
angiogenesis: opportunities and challenges, Chem. Soc. Rev., 49 (2020) 5008–5057. doi: 
10.1039/C8CS01021H 
 [62] M. Colilla, M. Vallet-Regi, Targeted Stimuli-Responsive Mesoporous Silica 
Nanoparticles for Bacterial Infection Treatment Int. J. Mol. Sci. 2020, 21, 8605; 
doi:10.3390/ijms21228605. 
[63] Q.H. Shi, J.F. Wang, J.P. Zhang, J. Fan, G.D. Stucky, Rapid‐setting, mesoporous, 
bioactive glass cements that induce accelerated in vitro apatite formation. Adv. Mater., 18 








[64] A.J. Salgado, O. P. Coutinho, R. L. Reis, Bone Tissue Engineering: State of the Art and 
Future Trends. Macromol. Biosci. 4 (2004) 743–65. doi: 10.1002/mabi.200400026. 
[65] M. Cicuendez, M.T. Portolés, I. Izquierdo-Barba, M. Vallet-Regí, New Nanocomposite 
System with Nanocrystalline Apatite Embedded into Mesoporous Bioactive Glass, Chem. 
Mater. 24 (2012) 1100–1106. doi: 10.1021/cm203416x.  
[66] C. Heras, S. Sanchez-Salcedo, D. Lozano, J. Peña, P. Esbrit, M. Vallet-Regi, A.J. 
Salinas, Osteostatin potentiates the bioactivity of mesoporous glass scaffolds containing 
Zn2+ ions in human mesenchymal stem cells. Acta Biomater. 89 (2019) 359–371. doi: 
10.1016/j.actbio.2019.03.033. 
[67] S. Shruti, A.J. Salinas, G. Lusvardi, G. Malavasi, L. Menabue, M. Vallet-Regi, 
Mesoporous bioactive scaffolds prepared with cerium-, gallium- and zinc-containing 
glasses. Acta Biomater. 9 (2013) 4836–4844. doi: 10.1016/j.actbio.2012.09.024. 
[68] Y. Zhu, S. Kaskel, Comparison of the in vitro bioactivity and drug release property of 
mesoporous bioactive glasses (MBGs) and bioactive glasses (BGs) scaffolds. Micropor. 
Mesopor. Mater. 118 (2009) 176–182. doi: 10.1016/j.micromeso.2008.08.046. 
[69] J. Jiménez-Holguín, A. López-Hidalgo, S. Sánchez-Salcedo, J. Peña, M. Vallet-Regí, 
A.J. Salinas, Strontium-Modified Scaffolds Based on Mesoporous Bioactive 
Glasses/Polyvinyl Alcohol Composites for Bone Regeneration, Materials. 13 (2020) 5526. 
doi:10.3390/ma13235526  
[70] C. Wu, J. Chang, Mesoporous bioactive glasses: structure characteristics, drug/growth 
factor delivery and bone regeneration application, Interface Focus. 2 (2012) 2292–306 
doi: 10.1098/rsfs.2011.0121.  
[71] S. Bano, M. Akhtar, M. Yasir, M. Salman Maqbool, A. Niaz, A. Wadood, M-A-U. 
Rehman. Synthesis and Characterization of Silver-Strontium (Ag-Sr)-Doped Mesoporous 
Bioactive Glass Nanoparticles. Gels. 7 (2021):34. doi: 10.3390/gels7020034.  
[72] P. Han, C. Wu, J. Chang, Y. Xiao, The cementogenic differentiation of periodontal 
ligament cells via the activation of Wnt/β-catenin signalling pathway by Li+ ions released 
from bioactive scaffolds. Biomaterials 33 (2012) 6370–6379. doi: 
10.1016/j.biomaterials.2012.05.061.  
[73] C.-L. Huang, W. Fang, B.-R. Huang, Y.-H. Wang, G.-C. Dong, T.-M. Lee, Bioactive glass 
as a nanoporous drug delivery system for teicoplanin, Appl. Sci. 10 (2020) 2595. doi: 
10.3390/app10072595 
[74] M. Hu, J. Fang, Y. Zhang, X. Wang, W. Zhong, Z. Zhou, Design and evaluation a kind of 
functional biomaterial for bone tissue engineering: Selenium/mesoporous bioactive glass 
nanospheres, J. Colloid Interface Sci. 579 (2020) 654–666. doi: 
10.1016/j.jcis.2020.06.122. 
[75] M. Nagrath, A.R. Yazdi, A. Rafferty, D. Daly, S.U. Rahman, R.C. Gallant, H. Ni, P.R. 
Arany, M.R. Towler, Tantalum-containing meso-porous glass fibres for hemostatic 








[76] E Varini, S Sánchez-Salcedo, G Malavasi, G Lusvardi, M Vallet-Regí, A:J: Salinas, 
Cerium (III) and (IV) containing mesoporous glasses/alginate beads for bone 
regeneration: Bioactivity, biocompatibility and reactive oxygen species activity, Mater. 
Sci. Eng. C Mater. Biol. Appl. 105 (2019) 109971. doi: 10.1016/j.msec.2019.109971. 
[77] Y. Zhang, X. Wang, Y. Su, D. Chen, W. Zhong, A doxorubicin delivery system: 
Samarium/mesoporous bioactive glass/alginate composite microspheres, Mater. Sci. 
Eng. C, 67 (2016) 205–213, doi: 10.1016/j.msec.2016.05.019. 
[78] Y. Zhang, M. Hu, X. Wang, Z. Zhou, Y. Liu. Design and evaluation of Europium 
containing mesoporous bioactive glass nanospheres: Doxorubicin release kinetics and 
inhibitory effect on osteosarcoma MG 63 Cells. Nanomaterials (Basel). 8 (2018) 961. 
doi:10.3390/nano8110961.  
[79] X. Wang, Y. Zhang, C. Lin, W. Zhong. Sol-gel derived terbium-containing mesoporous 
bioactive glasses nanospheres: In vitro hydroxyapatite formation and drug delivery. 
Colloids Surf. B Biointerfaces. 160 (2017) 406–415. doi: 10.1016/j.colsurfb.2017.09.051.  
 [80] J. Li, X. Li, J. Li, X. Pu, J. Wang, Z. Huang, G.Yin, Effects of incorporated vanadium and 
its chemical states on morphology and mesostructure of mesoporous bioactive glass 
particles, Micropor. Mesopor. Mat, 319, (2021) 111061, doi: 
10.1016/j.micromeso.2021.111061. 
[81] V. Guduric, N. Belton, R.F. Richter, A. Bernhardt, J. Spangenberg, C. Wu, A. Lode, M. 
Gelinsky. Tailorable Zinc-Substituted Mesoporous Bioactive Glass/Alginate-
Methylcellulose Composite Bioinks, Materials. 14 (2021) 1225. doi: 
10.3390/ma14051225. 
[82] F. Kermani, S. Mollazadeh Beidokhti, F. Baino, Z. Gholamzadeh-Virany, M. Mozafari, S. 
Kargozar, Strontium- and Cobalt-Doped Multicomponent Mesoporous Bioactive Glasses 
(MBGs) for Potential Use in Bone Tissue Engineering Applications, Materials. 13 (2020) 
1348. doi: 10.3390/ma13061348.  
[83] B.R. Barrioni, S.M. de Carvalho, P. Naruphontjirakul, E.Norris, N.L. Kelly, J.V. Hanna, 
J.R. Jones, M.M. Pereira Cobalt-containing spherical glass nanoparticles for therapeutic 
ion release First published: 13 May 2021 doi: 10.1111/jace.17916. 
[84] F. Kurtuldu, N. Mutlu, M. Michálek, K. Zheng, M. Masar, L. Liverani, S.Chen, D. Galusek, 
A.R. Boccaccini, Cerium and gallium containing mesoporous bioactive glass 
nanoparticles for bone regeneration: Bioactivity, biocompatibility and antibacterial activity, 
Mater. Sci. Eng. C, 124 (2021) 112050, doi: 10.1016/j.msec.2021.112050. 
[85] F. Westhauser, S. Wilkesmann, Q. Nawaz Q, F. Hohenbild, F. Rehder, M. Saur, J. 
Fellenberg, A. Moghaddam, M.S.  Ali, W. Peukert, A. Boccaccini, Aldo. Effect of 
manganese, zinc, and copper on thebiological and osteogenic properties of mesoporous 
bioactive glass nanoparticles. J Biomed Mater Res. 109 (2021) 1457–1467. doiI: 
10.1002/jbm.a.37136.  
[86] Y. Zhang, Y. Liu, M. Li, S. Lu, J. Wang, The effect of iron incorporation on the in vitro 
bioactivity and drug release of mesoporous bioactive glasses, Ceram. Int. 39 (2013) 








[87] Ge, F.; Yu, M.; Yu, C.; Lin, J.; Weng, W.; Cheng, K.; Wang, H. Improved RhBMP-2 
Function on MBG Incorporated TiO2 Nanorod Films. Colloids Surf. B Biointerfaces 2017, 
150, 153–158. doi:10.1016/j.colsurfb.2016.11.030.  
[88] M. Miola, J. Massera, A. Cochis, A. Kumar, L. Rimondini, E. Vernè Tellurium: A new 
active element for innovative multifunctional bioactive glasses. Mater. Sci. Eng. C, Mater 
Biol Appl. 123 (2021) 111957. DOI: 10.1016/j.msec.2021.111957.  
[89] S. Sanchez-Salcedo, S. Shruti, A.J. Salinas, G. Malavasi, L. Menabue, M.Vallet-Regi, In 
vitro antibacterial capacity and cytocompatibility of SiO2–CaO–P2O5 meso-macroporous 
glass scaffolds enriched with ZnO. J. Mater. Chem. B 2 (2014) 4836–4847. ddoi: 
10.1039/C4TB00403E. 
[90] C. Heras, J. Jiménez-Holguín, A.L. Doadrio, M. Vallet-Regí, S. Sánchez-Salcedo, A.J. 
Salinas, Multifunctional antibiotic- and zinc- containing mesoporous bioactive glass 
scaffolds to fight bone infection. Acta Biomater. 114 (2020) 395–406. doi: 
10.1016/j.actbio.2020.07.044  
 [91] S. Sanchez-Salcedo, G. Malavasi, A.J. Salinas, G. Lusvardi, L. Rigamonti, L. Menabue, 
M. Vallet-Regi, Highly-bioreactive silica-based mesoporous bioactive glasses enriched 
with gallium(III). Materials 11 (2018) 367. doi: 10.3390/ma11030367. 
[92] Jiménez-Holguín, J.; Sánchez-Salcedo, S.; Vallet-Regí, M.; Salinas, A. Development 
and evaluation of copper-containing mesoporous bioactive glasses for bone defects 
therapy. Micropor Mesopor. Mater. 308 (2020) 110454. doi: 
10.1016/j.micromeso.2020.110454]. 
[93] R. Pérez, S. Sanchez-Salcedo, D. Lozano, C. Heras, P. Esbrit, M. Vallet-Regí, A. J. 
Salinas, Osteogenic effect of ZnO-mesoporous glasses loaded with osteostatin, 
Nanomaterials 8 (2018) 592. doi: 10.3390/nano8080592.  
[94] P. Balasubramanian, A.J. Salinas, S. Sánchez-Salcedo, R. Detsch, M.  Vallet Regí, A.R. 
Boccaccini, Induction of VEGF secretion from bone marrow stromal cell line (ST-2) by the 
dissolution products of mesoporous silica glass particles containing CuO and SrO. J. 
Non-Cryst. Solids, 500 (2018) 217–224. doi: 10.1016/j.jnoncrysol.2018.07.073 
[95] A. Philippart, N. Gómez-Cerezo, D. Arcos, A.J. Salinas, E. Boccardi, M. Vallet-Regi, A.R. 
Boccaccini, Novel ion-doped mesoporous glasses for bone tissue engineering: Study of 
their structural characteristics influenced by the presence of phosphorous oxide, J. Non-
Cryst. Solids, 455 (2017) 90–97, doi: 10.1016/j.jnoncrysol.2016.10.031. 
[96] A.L. Doadrio, A.J. Salinas, J.M. Sánchez-Montero, M. Vallet-Regí Drug release from 
ordered mesoporous silicas. Curr. Pharm. Des. 21, (2015) 6189–6213. doi 
10.2174/1381612822666151106121419. 
[97] J. C Berkmann, A. X. Herrera Martin, C. Pontremoli, K. Zheng, C.H. Bucher, A. 
Ellinghaus, A.R, Boccaccini, S.Fiorilli, C-Vitale Brovarone, G.N. Duda, K.Schmidt-Bleek, 
In vivo validation of spray-dried mesoporous bioactive glass microspheres acting as 
prolonged local release systems for BMP-2 to induce bone regeneration. Pharmaceutics 








[98] J-H. Lee, P. Parthiban, G-Z. Jin, J.C. Knowles, H-W. Kim, Materials roles for promoting 
angiogenesis in tissue regeneration. Prog. Mater. Sci, 117 (2020) 100732, doi: 
10.1016/j.pmatsci.2020.100732. 
[99] D. Lozano, J Gil-Albarova, C. Heras, S. Sánchez-Salcedo, V.E. Gómez-Palacio, A. 
Gómez-Blasco, J.C. Doadrio, M. Vallet-Regí, A.J. Salinas, ZnO-mesoporous glass 
scaffolds loaded with osteostatin and mesenchymal cells improve bone healing in a rabbit 
bone defect, J. Mater. Sci.: Mater. Med. 31 (2020) 1–11. doi: 10.1007/s10856-020-
06439-w. 
[100] P. Sun, Q. Zhang, W. Nie, X. Zhou, L. Chen, H. Du, S. Yang, Z. You, J. He, C. He, 
Biodegradable Mesoporous Silica Nanocarrier Bearing Angiogenic QK Peptide and 
Dexamethasone for Accelerating Angiogenesis in Bone Regeneration, ACS Biomater. 
Sci. Eng. 5 (2019) 6766–6778. doi: 10.1021/acsbiomaterials.9b01521 
[101] K. Dashnyam, G.-Z. Jin, J.-H. Kim, R. Perez, J.-H. Jang, H.-W. Kim, Promoting 
angiogenesis with mesoporous microcarriers through a synergistic action of delivered 
silicon ion and VEGF, Biomaterials 116 (2017) 145–157 doi: 
10.1016/j.biomaterials.2016.11.053.  
[102] K.A. Bithi, H. Minami, M.K. Hossain, M.M. Rahman, M.A. Rahman, M.A. Gafur, H. 
Ahmad, Cationic polyelectrolyte grafted mesoporous magnetic silica composite particles 
for targeted drug delivery and thrombolysis, Materialia 11 (2020) 100676. doi: 
10.1016/j.mtla.2020.100676 
[103] M. Shi, Y. Zhou, J. Shao, Z. Chen, B. Song, J. Chang, C. Wu, Y. Xiao, Stimulation of 
osteogenesis and angiogenesis of hBMSCs by delivering Si ions and functional drug from 
mesoporous silica nanospheres, Acta Biomater. 21 (2015) 1785–89. doi: 
10.1016/j.actbio.2015.04.019.  
[104] Z. Tabia, K. El Mabrouk, M. Bricha, K. Nouneh, Mesoporous bioactive glass 
nanoparticles doped with magnesium: drug delivery and acellular in vitro bioactivity, RSC 
Adv. 9 (2019) 12232–12246. doi: 10.1039/C9RA01133A- 
[105] M.M. Farag, Z.M Al-Rashidy, M.M Ahmed, In vitro drug release behavior of Ce-doped 
nano-bioactive glass carriers under oxidative stress. J Mater Sci: Mater Med. 30, (2019). 
18, doi:10.1007/s10856-019-6220-3. 
[106] G.K. Pouroutzidou, L. Liverani, A. Theocharidou, I. Tsamesidis, M. Lazaridou, E. 
Christodoulou, A. Beketova, C. Pappa, K.S. Triantafyllidis, A:D. Anastasiou, L. 
Papadopoulou, D.N. Bikiaris, A:R: Boccaccini, E. Kontonasaki, Synthesis and 
Characterization of Mesoporous Mg- and Sr-Doped Nanoparticles for Moxifloxacin Drug 
Delivery in Promising Tissue Engineering Applications. Int. J. Mol. Sci. 22 (2021) 577. 
doi: 10.3390/ijms22020577. 
[107] C.-L. Huang, W. Fang, B.-R. Huang, Y.-H. Wang, G.-C. Dong, T.-M. Lee, Bioactive 
glass as a nanoporous drug delivery system for teicoplanin, Appl. Sci. 10 (2020) 2595. 








[108] O. Saneei Siavashy, N. Nabian, S.M. Rabiee, Titanium Dioxide Nanotubes 
Incorporated Bioactive Glass Nanocomposites: Synthesis, Characterization, Bioactivity 
Evaluation and Drug Loading, Int. J. Eng. 34 (2021) 1–9. doi: 10.5829/ije.2021.34.01a.01. 
[109] D. Arcos, A. Lopez-Noriega, E. Ruiz-Hernandez, O. Terasaki, M. Vallet-Regi, Ordered 
mesoporous microspheres for bone grafting and drug delivery. Chem. Mater. 21, (2009) 
1000–1009. doi.org/10.1021/cm801649z. 
[110] S. Garg, S. Thakur, A. Gupta, G. Kaur, O.P. Pandey, Antibacterial and anticancerous 
drug loading kinetics for (10-x)CuO-xZnO-20CaO-60SiO2-10P2O5 (2 </= x </= 8) 
mesoporous bioactive glasses, J. Mater. Sci. Mater. Med. 28 (2017) 11. doi: 
10.1007/s10856-016-5827-x. 
[111] N. Aslankoohi, K. Mequanint, Poly(ester amide)–Bioactive Glass Hybrid Biomaterials 
for Bone Regeneration and Biomolecule Delivery, ACS Appl. Bio Mater. 3 (2020) 3621–
3630. doi.org/10.1021/acsabm.0c00257 
[112] I.I. Althagafi, S.A. Ahmed, W.A. El-Said, Colorimetric aflatoxins immunoassay by using 
silica nanoparticles decorated with gold nanoparticles, Spectrochim. Acta A, 246 (2021) 
118999. doi: 10.1016/j.saa.2020.118999.  
[113] M.S.U. Rahman, M.A. Tahir, S. Noreen, M. Yasir, I. Ahmad, M.B. Khan, K.W. Ali, M. 
Shoaib, A. Bahadur, S. Iqbal, Magnetic mesoporous bioactive glass for synergetic use in 
bone regeneration, hyperthermia treatment, and controlled drug delivery, RSC Adv. 10 
(2020) 21413–21419. doi: 10.1039/d0ra08656h. 
[114] V.A. Tran, K.S. Van Giau Vo, S.-W. Lee, S.S.A. An, Multimodal mesoporous silica 
nanocarriers for dual stimuli-responsive drug release and excellent photothermal ablation 
of cancer cells, Int. J. Nanomedicine 15 (2020) 7667. doi:10.2147/IJN.S254344. 
[115] B. Sui, X. Liu, J. Sun, Dual-Functional Dendritic Mesoporous Bioactive Glass 
Nanospheres for Calcium Influx-Mediated Specific Tumor Suppression and Controlled 
Drug Delivery in Vivo, ACS Appl. Mater. Interfaces 10 (2018) 23548–23559. doi: 
10.1021/acsami.8b05616.  
[116] J.C. Berkmann, A.X. Herrera Martin, C. Pontremoli, K. Zheng, C.H. Bucher, A. 
Ellinghaus, A.R. Boccaccini, S. Fiorilli, C. Vitale Brovarone, G.N. Duda, K. Schmidt-Bleek. 
In Vivo Validation of Spray-Dried Mesoporous Bioactive Glass Microspheres Acting as 
Prolonged Local Release Systems for BMP-2 to Support Bone Regeneration. 
Pharmaceutics. 12 (2020) 823. doi: 10.3390/pharmaceutics12090823. 
[117] L. Mosqueira, B.R. Barrioni, T. Martins, N.M. Ocarino, R. Serakides, M.M. Pereira, In 
vitro effects of the co-release of icariin and strontium from bioactive glass submicron 
spheres on the reduced osteogenic potential of rat osteoporotic bone marrow 
mesenchymal stem cells, Biomed. Mater. 15 (2020). 055023 doi: 10.1088/1748-
605X/ab9095. 
[118] C. Wu, W. Fan, M. Gelinsky, Y. Xiao, P. Simon, R. Schulze, T. Doert, Y. Luo, G. 
Cuniberti, Bioactive SrO–SiO2 glass with well-ordered mesopores: Characterization, 









[119] J.H. Lee, N. Mandakhbayar, A. El-Fiqi, H.W. Kim, Intracellular co-delivery of Sr ion and 
phenamil drug through mesoporous bioglass nanocarriers synergizes BMP signaling and 
tissue mineralization, Acta Biomater. 60 (2017) 93–108. doi: 
10.1016/j.actbio.2017.07.021. 
 [120] T. Xin, J. Mao, L. Liu, J. Tang, L. Wu, X. Yu, Y. Gu, W. Cui, L. Chen, Programmed 
Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 and Inorganic 
Ion Composite Hydrogel as Artificial Periosteum, ACS Appl. Mater. Interfaces 12 (2020) 
6840-6851. doi.org/10.1021/acs.chemmater.0c03018.  
[121] L. Casarrubios,. A. Polo-Montalvo, M.C. Serrano, M.J. Feito, M. Vallet-Regí, D. Arcos, 
M.T. Portolés, Effects of Ipriflavone- Loaded Mesoporous Nanospheres on the 
Differentiation of Endothelial Progenitor Cells and Their Modulation by Macrophages. 
Nanomaterials, 11 (2021) 1102. doi:.10.3390/nano11051102.  
[122] S. Chitra, P. Bargavi, M. Balasubramaniam, R.R. Chandran, S. Balakumar, Impact of 
copper on in vitro biomineralization, drug release efficacy and antimicrobial properties of 
bioactive glasses, Mater. Sci. Eng. C 109 (2020) 110598.  doi: 
10.1016/j.msec.2019.110598. 
[123] K.A. Bithi, H. Minami, M.K. Hossain, M.M. Rahman, M.A. Rahman, M.A. Gafur, H. 
Ahmad, Cationic polyelectrolyte grafted mesoporous magnetic silica composite particles 
for targeted drug delivery and thrombolysis, Materialia 11 (2020) 100676. doi: 
10.1016/j.mtla.2020.100676.  
[124] Fu S, Du X, Zhu M, Tian Z, Wei D, Zhu Y. 3D printing of layered mesoporous bioactive 
glass/sodium alginate-sodium alginate scaffolds with controllable dual-drug release 
behaviors. Biomed. Mater. 14 (2019)  065011. doi: 10.1088/1748-605X/ab4166.  
[125] De Cremer K, Braem A, Gerits E, De Brucker K, Vandamme K, Martens JA, Michiels J, 
Vleugels J, Cammue BP, Thevissen K. Controlled release of chlorhexidine from a 
mesoporous silica-containing macroporous titanium dental implant prevents microbial 
biofilm formation. Eur. Cell Mater. 33 (2017) 13–27. doi: 10.22203/eCM.v033a02.  
[126] S. Shruti, A.J. Salinas, E. Ferrari, G. Malavasi, G. Lusvardi, A.L. Doadrio, L. Menabue, 
M. Vallet-Regi, Curcumin release from cerium, gallium and zinc containing mesoporous 
bioactive glasses. Micropor. Mesopor. Mat. 180 (2013) 92–101. doi: 
10.1016/j.micromeso.2013.06.014.   
[127] M.T. Matter, S. Probst, S. Läuchli, I.K. Herrmann, Uniting Drug and Delivery: Metal 
Oxide Hybrid Nanotherapeutics for Skin Wound Care, Pharmaceutics, 12 (2020) 780. doi: 
10.3390/pharmaceutics12080780. 
[128] N. Aslankoohi, K. Mequanint, Poly(ester amide)–Bioactive Glass Hybrid Biomaterials 
for Bone Regeneration and Biomolecule Delivery, ACS Appl. Bio Mater. 3 (2020) 3621–
3630. doi: 10.1021/acsabm.0c00257. 
 [129] X. Li, X. Wang, Z. Hua, J. Shi, One-pot synthesis of magnetic and mesoporous 
bioactive glass composites and their sustained drug release property, Acta Mater. 56 








[130] Lin HM, Wang WK, Hsiung PA, Shyu SG. Light-sensitive intelligent drug delivery 
systems of coumarin-modified mesoporous bioactive glass. Acta Biomater. 2010 
Aug;6(8):3256-63. doi: 10.1016/j.actbio.2010.02.014.  
[131] Salètes M, Vartin M, Mocquot C, Chevalier C, Grosgogeat B, Colon P, Attik N. 
Mesoporous Bioactive Glasses Cytocompatibility Assessment: A Review of In Vitro 
Studies. Biomimetics (Basel) 6 (2021) 9. doi: 10.3390/biomimetics6010009.  
[132] M.R. Iaquinta, E. Mazzoni, I. Bononi, J.C. Rotondo, C. Mazziotta, M. Montesi, S. Sprio, 
A. Tampieri, M. Tognon, F. Martini. Adult Stem Cells for Bone Regeneration and Repair. 
Front Cell Dev Biol. 7 (2019) 268. doi: 10.3389/fcell.2019.00268. 
[133] A. Oryan,   A. Kamali,  A. Moshiri,  M. Baghaban Eslaminejad.  Role of Mesenchymal 
Stem Cells in Bone Regenerative Medicine: What Is the Evidence?  Cells Tissues 
Organs 204 (2017) 59–83 doi: 10.1159/000469704.  
[134] O. Chaparro, I. Linero,  Regenerative Medicine: A New Paradigm in Bone 
Regeneration, in: Advanced Techniques in Bone Regeneration. In Tech (2016). 
doi:10.5772/62523. 
[135] G. Battafarano, M. Rossi M, V. De Martino, F. Marampon, L. Borro, A. Secinaro, A. Del 
Fattore A. Strategies for Bone Regeneration: From Graft to Tissue Engineering. Int. J. 
Mol. Sci. 22 (2021) 1128. doi: 10.3390/ijms22031128.  
[136] A. Anand, P. Das, S.K. Nandi, B. Kundu, Development of antibiotic loaded mesoporous 
bioactive glass and its drug release kinetics. Ceram. Int. 46 (2020) 5477–5483. DOI: 
10.1016/j.msec.2019.110180. 
[137] V. Lalzawmliana, A. Anand, M. Roy, B. Kundu, S.K. Nandi, Mesoporous bioactive 
glasses for bone healing and biomolecules delivery. Mater. Sci. Eng.: C (2020) 106, 
110180. DOI: 10.1016/j.msec.2019.110180. 
[138] C. Nirmala, R. Puvanakrishnan, Protective role of curcumin against isoproterenol 
induced myocardial infarction in rats. Mol. Cell. Biochem. 159 (1996) 85–93. DOI: 
10.1007/BF00420910.  
[139] S. Fiorilli, M. Pagani, E. Boggio, C.L.Gigliotti, C. Dianzani, R. Gauthier, C. Pontremoli, 
G.Montalbano, U. Dianzani, C. Vitale-Brovarone Sr-Containing Mesoporous Bioactive 
Glasses Bio-Functionalized with Recombinant ICOS-Fc: An In Vitro Study. Nanomaterials 
11 (2021) 321. doi: 10.3390/nano11020321.  
[140] S.Y. Teow, K. Liew, S.A. Ali, A.S. Khoo, S.C. Peh. Antibacterial Action of Curcumin 
against Staphylococcus aureus: A Brief Review. J. Trop. Med.  (2016) 2016:2853045. 
doi: 10.1155/2016/2853045.  
[141] P. Anand, C. Sundaram, S. Jhurani, A.B. Kunnumakkare, B.B. Aggarwal, Curcumin 
and cancer: an “old-age” disease with an “age-old” solution, Cancer Lett. 267 (2008) 








[142] A.L. Doadrio, J.M. Sánchez-Montero, J.C. Doadrio, A.J. Salinas, M. Vallet-Regí, A 
molecular model to explain the controlled release from SBA-15 functionalized with 









Declaration of interests 
 
☒ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☐The authors declare the following financial interests/personal relationships which may be considered 
as potential competing interests:  
 
 
 
 
 
 
Jo
urn
al 
Pr
e-p
roo
f
